Blackstone Buys Ayumi

Blackstone buys Ayumi.
Ayumi Pharmaceutical is a Japanese specialty pharmaceutical company focused on anti-rheumatism and orthopedics.
Ayumi’s prize anodyne product is Calonal. An acetaminophen drug with strong brand recognition among doctors, pharmacists, and patients. Calonal is the prescription of choice for its real and safe treatment of chronic pain. Ayumi is the anti-rheumatism market leader, with a complete range of remedies. Synthetic and biosimilar products are prescribed to patients across all stages. Ayumi also leads the Japanese biosimilar market. This notable emergent healing mode is both effective and efficient for patients and the national health service system.
Atsuhiko Sakamoto of Blackstone said: ‘We are delighted to announce our new partnership with Ayumi. Under the leadership of its seasoned management team, Ayumi has established a robust foundation as a leading specialty pharmaceutical company in the field of rheumatism and orthopedics – with world-class medical and scientific capabilities. We look forward to working with the Company to leverage Blackstone’s global footprint and ability in this sector to help Ayumi meet the growing need for its anti-rheumatism and orthopedic products, invest in new, cutting-edge treatments and products, and continue supporting the Company’s mission of improving patient health.’
Ouchi Hikaru of Ayumi said ‘It's a great honor to announce our new partnership with Blackstone to further speed up our growth. Although we have already established a strong platform of growth in partnership with Unison Capital, from orthopedic therapeutic areas to anti-rheumatism areas and further through the new introduction of biosimilar products, we will need more investment for future growth. We have great expectations for our new shareholder to further enhance our presence in the Japanese pharmaceutical industry and to continue providing drug treatments that contribute to patients and to society.’

Comments

Post a Comment

Popular posts from this blog

Pepsi Buys Rockstar

Pepsi buys Rockstar .     P epsiCo buys Rockstar Energy Beverages for $3.85 billion.     Founded in 2001, Rockstar is drinks designed for people leading an active lifestyle. Available in 20 flavors at convenience and grocery stores in 30 countries. Distributed by PepsiCo in North America since 2009. Supporting the Rockstar lifestyle across the globe through action sports, motorsports, and live music. Pepsi's energy portfolio also includes Kickstart , GameFuel, and Amp Energy.     The deal reflects the shift from reliance on sales of sugary, fizzy drinks toward options ranging from tea and coffee to still and sparkling water varieties, which appeal to health-conscious and younger consumers. Neither PepsiCo nor Coca-Cola owns a major brand in the energy drinks category, which is forecast to grow to more than $80 billion over the next five years and is now dominated by Red Bull.     2 00 countries and territories around the world enjoy ...
Read more

Compass Buys Marucci

Compass buys Marucci.     Compass Diversified Holdings buys Marucci Sports for $200 million.     Marucci Sports was founded in 2009 by Kurt Ainsworth, a retired pitcher for the San Francisco Giants and Baltimore Orioles, Joe Lawrence, a former second baseman for the Toronto Blue Jays, and Reed Dickens, a former White House Assistant Press Secretary under George W. Bush.     Marucci ’s first buy was Marucci Bat Company, launched out of a backyard shed in 2004. Ainsworth then led the buyout of an Amish-run Pennsylvania wood mill in 2008. This solidified Marucci's superior wood supply, and it still supplies all Marucci's wood today. In 2017 Marucci bought Victus , a baseball equipment maker known for its edgy designs and big attitude.     With vertically cohesive wood bat production, a global supplier group, and a client base of MVPs and World Series winners, Marucci and Victus are the top two bats among Big League players. T...
Read more

Gilead Buys Forty Seven

Gilead buys Forty Seven.     Gilead Sciences buys Forty Seven for $4.9 billion.     Forty Seven is a clinical-stage immuno-oncology firm developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on tech licensed from Stanford. Forty Seven’s lead program, magrolimab , is a monoclonal antibody against the CD47 receptor, a ‘don’t eat me’ signal that cancer cells commandeer to avoid being ingested by macrophages. Evaluated ant ibodies are in many clinical studies of patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. These assets complement the cell therapy franchise Gilead added with its 2017 buy of Kite Pharma .     Beyond magrolimab , Forty Seven is fixing to advance two more compounds into clinical testing. Developing FSI-174, an anti-cKIT antibody, in combination with magrolimab creates a novel, all-antibody conditioning regimen to address ...
Read more